ZYBERNO
Stock Report
Updated Aug 31, 2026

Tandem Diabetes Care, Inc. (TNDM)

Healthcare • NASDAQ

$21.43

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
20.0/100
POOR BUSINESS
Tandem Diabetes Care, Inc. (TNDM) scores 20/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
-100.0%
Overvalued
Growth gap unavailable — insufficient data for reverse DCF calculation.
🎯 Expected Annual Return
-52.6%
Margin of Safety convergence — your return if the market re-prices to intrinsic value (5-yr annualised)
0.4%
Yield + growth — what the business alone earns you, even if the market never re-rates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-46.0%)
Debt-to-Equity (Solvency Risk):CRITICAL (2.10x)
Operating Margin (Operational Efficiency):CRITICAL (-4.4%)
Return on Capital (Capital Efficiency):CRITICAL (-4.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Tandem Diabetes Care, Inc. (TNDM) stock report — Zyberno Score 20/100 (POOR BUSINESS), Margin of Safety -100.0%, -53% expected annual return. Full financial analysis on Zyberno.

According to Zyberno's DCF model, Tandem Diabetes Care, Inc. (TNDM) trades at $21.43 against an estimated intrinsic value per share of $0.44 — a -100.0% Margin of Safety based on Owner Earnings of $2.15M TTM, projected at 3.1% growth for 10 years with a 2.5% terminal growth rate. Zyberno's model translates this into a 5-year expected return of -52.6% annually.

Over the trailing twelve months, TNDM generated $2.15M in Owner Earnings. Capital was deployed as follows: $23.25M invested in capital expenditures. Reinvestment rate: -6.6%. Owner Earnings have grown at 3.1% annually over the trailing five years using log-linear regression.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:21.43
Market Cap:$1.48B

Valuation Multiples (3)

P/B Ratio:11.34x
P/S Ratio:1.42x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.10B

Price Action & Momentum (3)

Momentum Percentile:23 / 100
% of 52-Week High:72.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-6.2%
Reinvestment Rate:-6.6%
Fundamental Growth Rate (g):0.3%

Margin Analysis (3)

Operating Margin Ttm:-4.4%
Net Margin Ttm:-6.1%
Ebitda Margin:-3.1%

TTM Performance (3)

Gross Margin Ttm:56.0%
Operating Margin Ttm:-4.4%
Net Margin Ttm:-6.1%

Yield Metrics (3)

Earnings Yield:-$4.34
Owner Earnings Yield:$0.15
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:64.5%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):10.4%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):34.9%
Operating Cash Flow Growth Rate (Linear):24.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.18x
Quick Ratio:2.65x
Cash Ratio:0.25x

Leverage Analysis (3)

Debt To Equity Ttm:2.10x
Debt-to-Equity Ratio:2.10x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-21.29x
Times Interest Earned:-21.29

Capital Structure (4)

Working Capital:551,634,000.00
Cash And Cash Equivalents:62,818,000.00
Long Term Debt:$602.58M
Net Debt:$621.14M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.04B
Linear Growth: 10.4%
📊 Click to view full TNDM Revenue analysis & methodology →
Cost Of Revenue Ttm:$458.10M

Profitability Breakdown (2)

Gross profit TTM: $583.32M
Linear Growth: 14.2%
📊 Click to view full TNDM Gross Profit analysis & methodology →
-$45.80M

Bottom Line Performance (3)

-$63.32M
Income Before Tax:-$240.81M
Ebitda Ttm:-32,303,000.00

Operating Expenses (5)

Operating Expenses:629,115,000.00
R And D Expense:187,746,000.00
Sga Expense:441,369,000.00
Income Tax Expense:$2.32M
Interest Expense:8,794,000.00

Expense Ratios (3)

R And D To Revenue Percentage:73.8%
Sga To Revenue Percentage:173.4%
Ebitda Margin:-3.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.15B
Current Assets:$804.64M
Ppe Net:84,501,000.00
Goodwill:0.00
Intangible Assets:$11.72M

Liability Structure (4)

Total Liabilities:1,023,814,000.00
Current Liabilities:253,005,000.00
Long Term Debt:$602.58M
Short Term Debt:$81.38M

Equity & Capital (3)

Equity:$130.39M
Retained Earnings:-$1.29B
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:162,065,000.00
Inventory:135,106,000.00
Accounts Payable:64,130,000.00

Special Items (2)

Contract Liabilities:8,430,000.00
Stock Based Compensation:15,741,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $19.61M
Linear Growth: 24.8%
Free cash flow TTM: -$3.64M
Linear Growth: 34.9%
📊 Click to view full TNDM Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$195.45M
Capital Expenditures Ttm:23,251,000.00

Financing Activities (3)

Financing Cash Flow:$274.16M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:-6,730,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:13,492,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.93
-$0.93
Earnings Per Share Ttm:-$0.92

Revenue & Cash Per Share (2)

Sales Per Share Ttm:15.09
Operating Cash Flow Per Share:-$0.14

Book Value & Capital (2)

Book Value Per Share:$1.89
Cash Per Share:0.91

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.03x
Working Capital Turnover Ttm:1.89x

Receivables Management (2)

Receivables Turnover Ttm:6.43x
Days Sales Outstanding Ttm:56.80

Inventory Management (2)

Inventory Turnover Ttm:3.39x
Days Inventory Outstanding Ttm:107.65

Payables & Cash Cycle (2)

Days Payable Outstanding:51.10
Cash Conversion Cycle:113.35
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (3)

Owner earnings TTM: $2.15M
Linear Growth: 3.1%
📊 Click to view full TNDM Owner Earnings analysis & methodology →
Owner Earnings Per Share:$0.03
Owner Earnings Yield:$0.15

Growth Assessment (1)

Owner Earnings Growth Rate:$3.11

Damodaran Growth Analysis (2)

Reinvestment Rate:-6.6%
Fundamental Growth Rate (g):0.3%

Intrinsic Value Models (1)

Return Scenarios (2)

Investment Assessment (1)

Buffett Assessment:Overvalued
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):10.4%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):34.9%
Operating Cash Flow Growth Rate (Linear):24.8%

Other Growth Rates (3)

Gross Profit Growth Rate (Linear):14.2%
Book Value Growth Rate (Linear):-27.6%
Owner Earnings Growth Rate:$3.11
C. Company Profile & Context

Corporate Information (6)

Symbol:TNDM
Company Name:Tandem Diabetes Care, Inc.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:69.01M
Shares Outstanding Basic:69.01M
Shares Outstanding Diluted:69.01M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 22:17:20 UTC
Data Timestamp:2026-08-31T22:17:20.124382
Scroll to Top